Systematic review and network meta-analysis of 20 RCTs (4,716 patients) with HR+ advanced breast cancer after CDK4/6i: in ESR1-mutated tumours, adding CDK4/6i or mTORi to oral SERDs improved PFS vs oral SERD/SERM/PROTAC alone (HR 0.44 and 0.45).
Meta-analysisn = 4,716
Escudero et al. Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis